The relationship between peptides and biomedicine is extremely close, and it is one of the core components of modern biomedicine. Simply put, peptides are a highly promising and valuable form of drug in the development of biomedicine, filling the key gap between small molecule chemical drugs and large molecule protein drugs.
1. The core advantage of peptides as drugs
Peptides are short chains (usually less than 50 amino acids) formed by connecting amino acids through peptide bonds, which give them unique advantages:
--High specificity and efficiency: Peptides can precisely target specific receptor, enzyme, or protein interaction interfaces like natural ligands (such as hormones, cytokines), resulting in high efficacy and relatively small side effects.
--Good safety: The metabolic products of peptides are amino acids, which are usually less toxic and immunogenic to the human body (compared to protein drugs).
--Between small and large molecules: Compared to small molecule drugs, peptides have stronger target selectivity and affinity; Compared to macromolecular drugs such as antibodies, peptides have a smaller molecular weight, relatively lower synthesis and production costs, and sometimes better tissue permeability.
2. Wide application of peptide drugs in biomedicine
Peptide drugs have been successfully applied in multiple major disease fields:
Metabolic diseases: The most classic example is insulin (usually classified as protein, but also polypeptide hormone) used for the treatment of diabetes. GLP-1 receptor agonists, such as liraglutide and semaglutide, are revolutionary peptide drugs in recent years that not only effectively lower blood sugar levels, but also help with weight loss and cardiovascular benefits.
Tumor treatment:
--Targeted therapy: such as GnRH analog (leuprorelin) used to treat prostate cancer.
--Radioisotope coupling: Linking peptides targeting tumors with radionuclides to achieve precise radiotherapy (such as Lu-177 DOTATATE for neuroendocrine tumors).
--Cell penetrating peptides: assist anti-tumor drugs in entering cells.
Anti infection: Certain natural antimicrobial peptides (such as bacteriocins) or peptide analogues can be used to combat drug-resistant bacteria.
Cardiovascular disease: such as nesiritide used for acute heart failure.
Diagnosis: Targeted peptide tracer used for imaging examinations such as PET-CT.
3. Challenges and technological innovation faced by peptide drug development
Despite its prominent advantages, peptide drugs also face challenges, which have driven advances in biopharmaceutical technology
(1) Poor stability: easily degraded by proteases in the body, with a short plasma half-life.
--Solution: Chemical modification of peptides (such as PEGylation), substitution of D-amino acids, cyclization, development of peptide analogs, etc.
(2) Oral administration is difficult: it is easily damaged by the gastrointestinal tract and has poor absorption.
--Solution: Develop new routes of administration (injection, inhalation, transdermal), or use absorption enhancers.
(3) Production cost: The chemical synthesis or biological expression cost of long-chain peptides is relatively high.
--Solution: Improve solid-phase synthesis technology and develop recombinant DNA production technology.
4. Frontiers and Future Trends
Peptides are the forefront of biomedical innovation:
--Multi functional peptides and conjugated drugs: Combining peptides with toxins, cytokines, antibody fragments (producing peptide drug conjugates, PDCs) or nanomaterials to achieve synergistic therapy.
--Cell penetrating peptides and drug delivery: As a "Trojan horse", they help large molecule drugs (such as nucleic acids and proteins) penetrate cell membranes, paving the way for gene therapy and other treatments.
--Bispecific/Multispecific Peptides: Simultaneously bind to two or more targets to produce more complex pharmacological effects.
--Artificial Intelligence and Computational Design: The use of AI to predict peptide structure, function, and optimize sequences has greatly accelerated the discovery of new peptide drugs.
